Yamada Y, Beltran H. Clinical and biological features of neuroendocrine prostate cancer. Curr Oncol Rep. 2021;23:15.
Article
PubMed
PubMed Central
Google Scholar
Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, Robinson BD, Troncoso P, Rubin MA. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014;38:756–67.
Article
PubMed
PubMed Central
Google Scholar
Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, Dhir R, Nelson JB, de la Taille A, Allory Y, Gerstein MB, Perner S, Pienta KJ, Chinnaiyan AM, Wang Y, Collins CC, Gleave ME, Demichelis F, Nanus DM, Rubin MA. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1:487–95.
Article
PubMed
PubMed Central
CAS
Google Scholar
Spetsieris N, Boukovala M, Patsakis G, Alafis I, Efstathiou E. Neuroendocrine and aggressive-variant prostate cancer. Cancers. 2020. https://doi.org/10.3390/cancers12123792.
Article
PubMed
PubMed Central
Google Scholar
Li Y, He Y, Butler W, Xu L, Chang Y, Lei K, Zhang H, Zhou Y, Gao AC, Zhang Q, Taylor DG, Cheng D, Farber-Katz S, Karam R, Landrith T, Li B, Wu S, Hsuan V, Yang Q, Hu H, Chen X, Flowers M, McCall SJ, Lee JK, Smith BA, Park JW, Goldstein AS, Witte ON, Wang Q, Rettig MB, Armstrong AJ, Cheng Q, Huang J. Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer. Sci Transl Med. 2019. https://doi.org/10.1126/scitranslmed.aax0428.
Article
PubMed
PubMed Central
Google Scholar
Wang Q, Li Z, Yang J, Peng S, Zhou Q, Yao K, Cai W, Xie Z, Qin F, Li H, Chen X, Li K, Huang H. Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer. Cancer biol med. 2021. https://doi.org/10.20892/j.issn.2095-3941.2020.0550.
Article
PubMed
PubMed Central
Google Scholar
Fléchon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis G, Joly F, Oudard S, Deplanque G, Zanetta S, Fargeot P, Priou F, Droz JP, Culine S. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Med Oncol. 2011;22:2476–81.
Google Scholar
Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, Troncoso P, Logothetis CJ. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002;20:3072–80.
Article
PubMed
CAS
Google Scholar
Wang HT, Yao YH, Li BG, Tang Y, Chang JW, Zhang J. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J Clin Oncol. 2014;32:3383–90.
Article
PubMed
Google Scholar
Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, Yamashita N, Fushimi A, Kui L, Samur M, Yamamoto M, Zhang Y, Zhang N, Hong D, Maeda T, Kosaka T, Wong KK, Oya M, Kufe D. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nat Commun. 2020;11:338.
Article
PubMed
PubMed Central
CAS
Google Scholar
Lovnicki J, Gan Y, Feng T, Li Y, Xie N, Ho CH, Lee AR, Chen X, Nappi L, Han B, Fazli L, Huang J, Gleave ME, Dong X. LIN28B promotes the development of neuroendocrine prostate cancer. J Clin Investig. 2020;130:5338–48.
Article
PubMed
PubMed Central
CAS
Google Scholar
Li Z, Qin F, Li H. Chimeric RNAs and their implications in cancer. Curr Opin Genet Dev. 2018;48:36–43.
Article
PubMed
CAS
Google Scholar
Shi X, Singh S, Lin E, Li H. Chimeric RNAs in cancer. Adv Clin Chem. 2021;100:1–35.
Article
PubMed
Google Scholar
Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Can Res. 2006;66:8347–51.
Article
CAS
Google Scholar
Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, Liao WW, Reynolds SM, Wyczalkowski MA, Yao L, Yu L, Sun SQ, Chen K, Lazar AJ, Fields RC, Wendl MC, Van Tine BA, Vij R, Chen F, Nykter M, Shmulevich I, Ding L. Driver fusions and their implications in the development and treatment of human cancers. Cell Rep. 2018;23:227-238.e223.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kumar-Sinha C, Kalyana-Sundaram S, Chinnaiyan AM. SLC45A3-ELK4 chimera in prostate cancer: spotlight on cis-splicing. Cancer Discov. 2012;2:582–5.
Article
PubMed
PubMed Central
CAS
Google Scholar
Luo Y, Du L, Yao Z, Liu F, Li K, Li F, Zhu J, Coppes RP, Zhang D, Pan Y, Gao S, H. Zhang, generation and application of inducible chimeric rna astn2-pappa(as) knockin mouse model. Cells. 2022;11(2):277.
Article
PubMed
PubMed Central
CAS
Google Scholar
Zhu D, Singh S, Chen X, Zheng Z, Huang J, Lin T, Li H. The landscape of chimeric RNAs in bladder urothelial carcinoma. Int J Biochem Cell Biol. 2019;110:50–8.
Article
PubMed
CAS
Google Scholar
Singh S, Qin F, Kumar S, Elfman J, Lin E, Pham LP, Yang A, Li H. The landscape of chimeric RNAs in non-diseased tissues and cells. Nucleic Acids Res. 2020;48:1764–78.
Article
PubMed
PubMed Central
CAS
Google Scholar
Wang Q, Wu W, Gao Z, Li K, Peng S, Fan H, Xie Z, Guo Z, Huang H. GADD45B is a potential diagnostic and therapeutic target gene in chemotherapy-resistant prostate cancer. Front Cell Dev Biol. 2021;9:716501.
Article
PubMed
PubMed Central
Google Scholar
Xie Z, Janczyk P, Zhang Y, Liu A, Shi X, Singh S, Facemire L, Kubow K, Li Z, Jia Y, Schafer D, Mandell JW, Abounader R, Li H. A cytoskeleton regulator AVIL drives tumorigenesis in glioblastoma. Nat Commun. 2020;11:3457.
Article
PubMed
PubMed Central
CAS
Google Scholar
Qin F, Song Z, Babiceanu M, Song Y, Facemire L, Singh R, Adli M, Li H. Discovery of CTCF-sensitive cis-spliced fusion RNAs between adjacent genes in human prostate cells. PLoS Genet. 2015;11:e1005001.
Article
PubMed
PubMed Central
CAS
Google Scholar
Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15:701–11.
Article
PubMed
PubMed Central
CAS
Google Scholar
Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32:5501–11.
Article
PubMed
PubMed Central
CAS
Google Scholar
Aparicio A, Logothetis CJ, Maity SN. Understanding the lethal variant of prostate cancer: power of examining extremes. Cancer Discov. 2011;1:466–8.
Article
PubMed
PubMed Central
Google Scholar
Wu H, Singh S, Xie Z, Li X, Li H. Landscape characterization of chimeric RNAs in colorectal cancer. Cancer Lett. 2020;489:56–65.
Article
PubMed
CAS
Google Scholar
Bader DA, McGuire SE. Tumour metabolism and its unique properties in prostate adenocarcinoma, nature reviews. Urology. 2020;17:214–31.
PubMed
Google Scholar
Xiao H, Wang J, Yan W, Cui Y, Chen Z, Gao X, Wen X, Chen J. GLUT1 regulates cell glycolysis and proliferation in prostate cancer. Prostate. 2018;78:86–94.
Article
PubMed
CAS
Google Scholar
Stoykova GE, Schlaepfer IR. Lipid metabolism and endocrine resistance in prostate cancer, and new opportunities for therapy. Int J mole sci. 2019;20(11):2626.
Article
CAS
Google Scholar
Park JW, Lee JK, Sheu KM, Wang L, Balanis NG, Nguyen K, Smith BA, Cheng C, Tsai BL, Cheng D, Huang J, Kurdistani SK, Graeber TG, Witte ON. Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science. 2018;362:91–5.
Article
PubMed
PubMed Central
CAS
Google Scholar
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–8.
Article
PubMed
CAS
Google Scholar
Sandoval GJ, Pulice JL, Pakula H, Schenone M, Takeda DY, Pop M, Boulay G, Williamson KE, McBride MJ, Pan J, St Pierre R, Hartman E, Garraway LA, Carr SA, Rivera MN, Li Z, Ronco L, Hahn WC, Kadoch C. Binding of TMPRSS2-ERG to BAF Chromatin remodeling complexes mediates prostate oncogenesis. Mol cell. 2018;71(4):554-566.e557.
Article
PubMed
PubMed Central
CAS
Google Scholar
Esgueva R, Perner S, LaFargue CJ, Scheble V, Stephan C, Lein M, Fritzsche FR, Dietel M, Kristiansen G, Rubin MA. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort, modern pathology. Mod Pathol. 2010;23(4):539–46.
Article
PubMed
PubMed Central
CAS
Google Scholar
Lasda EL, Blumenthal T. Trans-splicing. Wiley Interdiscip Rev RNA. 2011;2:417–34.
Article
PubMed
CAS
Google Scholar
Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster CS, Eeles R, Martin FL, Phillips DH, Crundwell M, Christmas T, Thompson A, Fisher C, Kovacs G, Cooper CS. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene. 2007;26:2667–73.
Article
PubMed
CAS
Google Scholar
Miyagi Y, Sasaki T, Fujinami K, Sano J, Senga Y, Miura T, Kameda Y, Sakuma Y, Nakamura Y, Harada M, Tsuchiya E. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Mod pathol. 2010;23:1492–8.
Article
PubMed
Google Scholar
Fu Z, Rais Y, Bismar TA, Hyndman ME, Le XC, Drabovich AP. Mapping Isoform abundance and interactome of the endogenous tmprss2-erg fusion protein by orthogonal immunoprecipitation-mass spectrometry assays. Mol cell proteomics. 2021;20:100075.
Article
PubMed
PubMed Central
CAS
Google Scholar
Deplus R, Delliaux C, Marchand N, Flourens A, Vanpouille N, Leroy X, de Launoit Y, Duterque-Coquillaud M. TMPRSS2-ERG fusion promotes prostate cancer metastases in bone. Oncotarget. 2017;8:11827–40.
Article
PubMed
Google Scholar
Delliaux C, Tian TV, Bouchet M, Fradet A, Vanpouille N, Flourens A, Deplus R, Villers A, Leroy X, Clézardin P, de Launoit Y, Bonnelye E, Duterque-Coquillaud M. TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases. Cancer Lett. 2018;438:32–43.
Article
PubMed
CAS
Google Scholar
Y. Qiao, X.M. Wang, R. Mannan, S. Pitchiaya, Y. Zhang, J.W. Wotring, L. Xiao, D.R. Robinson, Y.M. Wu, J.C. Tien, X. Cao, S.A. Simko, I.J. Apel, P. Bawa, S. Kregel, S.P. Narayanan, G. Raskind, S.J. Ellison, A. Parolia, S. Zelenka-Wang, L. McMurry, F. Su, R. Wang, Y. Cheng, A.D. Delekta, Z. Mei, C.D. Pretto, S. Wang, R. Mehra, J.Z. Sexton, A.M. Chinnaiyan. Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2, proceedings of the national academy of sciences of the United States of America. 2020; 118.
FitzGerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-Coll A, Fazli L, Rajput AB, Gleave ME, Cox ME, Ostrander EA, Stanford JL, Huntsman DG. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer. 2008;8:230.
Article
PubMed
PubMed Central
CAS
Google Scholar
Eguchi FC, Faria EF, Scapulatempo Neto C, Longatto-Filho A, Zanardo-Oliveira C, Taboga SR, Campos SG. The role of TMPRSS2:ERG in molecular stratification of PCa and its association with tumor aggressiveness: a study in Brazilian patients. Sci rep. 2014;4(1):5640.
Article
PubMed
PubMed Central
CAS
Google Scholar
Yang Y, Blee AM, Wang D, An J, Pan Y, Yan Y, Ma T, He Y, Dugdale J, Hou X, Zhang J, Weroha SJ, Zhu WG, Wang YA, DePinho RA, Xu W, Huang H. Loss of FOXO1 Cooperates with TMPRSS2-ERG overexpression to promote prostate tumorigenesis and cell invasion. Can Res. 2017;77:6524–37.
Article
CAS
Google Scholar
Reig Ò, Marín-Aguilera M, Carrera G, Jiménez N, Paré L, García-Recio S, Gaba L, Pereira MV, Fernández P, Prat A, Mellado B. TMPRSS2-ERG in blood and docetaxel resistance in metastatic castration-resistant prostate cancer. Eur Urol. 2016;70:709–13.
Article
PubMed
CAS
Google Scholar
Zammarchi F, Boutsalis G, Cartegni L. 5’ UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer. PLoS ONE. 2013;8:e49721.
Article
PubMed
PubMed Central
CAS
Google Scholar
Tian TV, Tomavo N, Huot L, Flourens A, Bonnelye E, Flajollet S, Hot D, Leroy X, de Launoit Y, Duterque-Coquillaud M. Identification of novel TMPRSS2: ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2. Oncogene. 2014;33:2204–14.
Article
PubMed
CAS
Google Scholar
Thangapazham R, Saenz F, Katta S, Mohamed AA, Tan SH, Petrovics G, Srivastava S, Dobi A. Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer. BMC cancer. 2014;14(1):16.
Article
PubMed
PubMed Central
Google Scholar
Wang Y, Xu L, Shi S, Wu S, Meng R, Chen H, Z. Jiang, deficiency of NEIL3 enhances the chemotherapy resistance of prostate cancer. Int J Mol Sci. 2021;22(8):4098.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kong DP, Chen R, Zhang CL, Zhang W, Xiao GA, Wang FB, Ta N, Gao X, Sun YH. Prevalence and clinical application of TMPRSS2-ERG fusion in Asian prostate cancer patients: a large-sample study in Chinese people and a systematic review. Asian J Androl. 2020;22:200–7.
Article
PubMed
Google Scholar
Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA, Sanda MG. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res. 2009;15:4706–11.
Article
PubMed
PubMed Central
CAS
Google Scholar
Qin F, Zhang Y, Liu J, Li H. SLC45A3-ELK4 functions as a long non-coding chimeric RNA. Cancer Lett. 2017;404:53–61.
Article
PubMed
CAS
Google Scholar
Chen R, Ren S, Yiu MK, Fai NC, Cheng WS, Ian LH, Naito S, Matsuda T, Kehinde E, Kural A, Chiu JY, Umbas R, Wei Q, Shi X, Zhou L, Huang J, Huang Y, Xie L, Ma L, Yin C, Xu D, Xu K, Ye Z, Liu C, Ye D, Gao X, Fu Q, Hou J, Yuan J, He D, Pan T, Ding Q, Jin F, Shi B, Wang G, Liu X, Wang D, Shen Z, Kong X, Xu W, Deng Y, Xia H, Cohen AN, Gao X, Xu C, Sun Y. Prostate cancer in Asia: a collaborative report. Asian J Urol. 2014;1:15–29.
Article
PubMed
Google Scholar
Zheng B, Ma YC, Ostrom RS, Lavoie C, Gill GN, Insel PA, Huang XY, Farquhar MG. RGS-PX1, a GAP for GalphaS and sorting nexin in vesicular trafficking. Science. 2001;294:1939–42.
Article
PubMed
CAS
Google Scholar
Deng H, Xiao H. The role of the ATP2C1 gene in Hailey-Hailey disease. Cell Mol Life Sci. 2017;74:3687–96.
Article
PubMed
CAS
Google Scholar